Search results
Novavax Stock May Soar 379%, According to Wall Street. Is the Stock a Buy Right Now?
Motley Fool via Yahoo Finance· 3 months agoNovavax (NASDAQ: NVAX) soared more than 2,700% early in the pandemic as investors bet on its ability...
Novavax (NVAX) Q4 Earnings & Revenues Miss Estimates, Stock Down
Zacks via Yahoo Finance· 1 year agoNovavax (NVAX) reports worse-than-expected financial performance in the fourth quarter of 2022, with...
Novavax's (NVAX) Updated COVID Jab Gets WHO Nod for Emergency Use
Zacks via Yahoo Finance· 5 months agoNovavax NVAX announced that the World Health Organization (“WHO”) has granted emergency use listing...
Will Novavax's Covid Booster Thesis Play Out? What The Survey Says
Investor's Business Daily· 2 years agoNovavax's Covid booster is preemptively gaining steam, according to the July IBD/TIPP Poll. The...
FDA authorizes Novavax as new alternative to mRNA COVID-19 vaccines
CBS News via Yahoo News· 2 years agoThe Food and Drug Administration has granted Novavax's COVID-19 vaccine emergency use authorization,...
Could Novavax Stock Help You Become a Millionaire?
Motley Fool via Yahoo Finance· 3 months agoNovavax (NASDAQ: NVAX) stock may have made some millionaires back in 2020. It was the height of the coronavirus vaccine race, and investors were betting...
IBD/TIPP Poll: There's Bad News For Novavax's Covid Vaccine
Investor's Business Daily· 2 years agoNovavax could struggle to find a U.S. market for its Covid vaccine, according to the latest IBD/TIPP...
Why Novavax Stock Rocketed 10% Higher Today
Motley Fool· 8 months agoWhat happened A potential upswing of COVID was the impetus behind a blast of interest in Novavax (NASDAQ: NVAX) stock on Tuesday. That morning, it was...
Novavax's updated COVID vaccine is here. What to know about the shot.
Yahoo Life Style via AOL· 7 months agoUnlike Moderna and Pfizer's mRNA vaccines, the Novavax vaccine utilizes a protein-based approach....
Why Novavax Fell Today Despite Its Sunny News
Motley Fool· 2 years agoNovavax's (NASDAQ: NVAX) Nuvaxovid vaccine against COVID-19 continues to rack up regulatory victories, but you'd never know that from the stock's performance on Monday. It fell by 2%, more or ...
